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ABSTRACT
Neutropenia represents one of the major dose-limiting toxicities of many current 
cancer therapies. To circumvent the off-target effects of cytotoxic chemotherapeutics, 
kinase inhibitors are increasingly being used as an adjunct therapy to target 
leukemia. In this study, we conducted a screen of leukemic cell lines in parallel 
with primary neutrophils to identify kinase inhibitors with the capacity to induce 
apoptosis of myeloid and lymphoid cell lines whilst sparing primary mouse and 
human neutrophils. We have utilized a high-throughput live cell imaging platform to 
demonstrate that cytotoxic drugs have limited effects on neutrophil viability but are 
toxic to hematopoietic progenitor cells, with the exception of the topoisomerase I 
inhibitor SN-38. The parallel screening of kinase inhibitors revealed that mouse and 
human neutrophil viability is dependent on cyclin-dependent kinase (CDK) activity but 
surprisingly only partially dependent on PI3 kinase and JAK/STAT signaling, revealing 
dominant pathways contributing to neutrophil viability. Mcl-1 haploinsufficiency 
sensitized neutrophils to CDK inhibition, demonstrating that Mcl-1 is a direct target 
for CDK inhibitors. This study reveals a therapeutic window for the kinase inhibitors 
BEZ235, BMS-3, AZD7762, and (R)-BI-2536 to induce apoptosis of leukemia cell lines 
whilst maintaining immunocompetence and hemostasis.
INTRODUCTION
Acute Myeloid Leukaemia (AML) is a 
heterogeneous disease characterised by an abundance 
of mutations in genes encoding signalling proteins, 
transcription factors, tumor suppressors and chromatin 
modifying proteins [1]. Cytogenetic profiling and 
molecular genetic analysis is used to stratify patients 
into low, intermediate and high-risk groups, and whilst 
low-risk groups respond well to conventional cytotoxic 
chemotherapy, the majority of patients do not [2]. Indeed, 
less than 40% of adults with AML are cured, with the 
situation being particularly poor for the elderly who often 
have co-morbid conditions, where median survival is 
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approximately 10 months [3]. Against this backdrop there 
has been a concerted effort over the last decade to develop 
targeted therapies for AML, with the aim to target specific 
genetic lesions driving oncogenesis [4]. In particular, 
there has been a considerable focus on the development of 
selective kinase inhibitors for the treatment of AML, such 
as FLT3 inhibitors for the ~30% of patients who possess 
activating FLT3 mutations [5, 6] .
Targeted therapies have also been proposed 
[7] for the treatment of T cell acute lymphoblastic 
leukemias (T-ALLs). T-ALL displays a variety of genetic 
complexities arising from mutations in signalling proteins, 
transcription factors and tumor suppressors. BCR-ABL 
inhibitors such as imatinib, nilotinib and dasatinib may be 
of use to ALL patients with ABL fusion proteins [8].
Of the hematological toxicities associated with 
chemotherapy regimes, neutropenia is the most common 
dose-limiting side-effect [9-12]. Neutropenia renders 
the immune system incapable of effective responses to 
many types of pathogens, and the duration and severity 
is strongly linked to morbidity and mortality [9], 
with average mortality being shorter for patients with 
hematological malignancies compared to those with 
solid tumors [13]. In addition neutropenia is associated 
with a significant economic burden due to treatment and 
hospitalization [13].
To better understand the clinical potential of 
targeted therapies in leukemia and particularly AML, we 
have screened a library of 95 known and well-studied 
kinase inhibitors and examined the apoptosis-inducing 
effect of these compounds against a panel of leukemia 
lines. In conjunction, we have used a live-cell imaging 
platform previously developed by us to determine if these 
compounds also induce apoptosis of neutrophils and 
hematopoietic progenitor cells, as a method of assessing 
their potential to cause neutropenia. With this combined 
experimental design we have identified individual kinase 
inhibitors that provide a therapeutic window for the 
effective treatment of leukemias with minimal effects 
on neutrophil viability. In addition, the data obtained 
in our neutrophil viability screen has identified kinase 
targets whose inhibition significantly impacts neutrophil 
survival via effects on Mcl-1 and may contribute directly 
to neutropenia in vivo.
RESULTS
Effect of compounds on leukemia cell proliferation
A library of 95 discrete kinase inhibitors was 
established with activity across all kinase families in 
the human kinome (Table 1). All compounds in the 
collection have been studied extensively with broad 
kinome selectivity data for most compounds available 
in the literature [18-20]. Many of the inhibitors are used 
therapeutically or are in advanced clinical development. 
In addition, the BH3 mimetic ABT-737 [21], a compound 
with potent activity against leukemias [22], was included 
as a control compound.
The activity of the kinase inhibitor collection against 
a panel of human leukemia cell lines was determined in 
cell viability assays run over 48 h using the Cell Titer Glo 
reagent. The cell lines examined consisted of five AML 
lines (MV4;11, HL-60, OCI-AML3, THP-1, U937), two 
chronic myeloid leukemia (CML) lines (K562 and KU-
812), two T-cell leukemia lines (MOLT4, JURKAT), and 
three additional leukemia lines (EOL-1, HEL.92.1.7, 
MEG-01), representing eosinophilic leukemia, 
erythroleukemia and megakaryoblastic leukemia, 
respectively. Compounds in this collection displayed a 
wide diversity of responses across the panel of cell lines 
(Figure 1A, Table 2). A substantial number of compounds 
showed potent activity against both MV4;11 and EOL-1 
cell lines, whereas other cell lines (HEL 92.1.7, THP-1 and 
MOLT-4) appeared largely resistant to effects on cellular 
viability over the timeframe of the experiment. A small 
number of compounds showed potent activity (IC50 ≤ 10 
nM) across most of the cell lines examined. These pan-
active compounds consist of the first-generation PI3K 
p110α (PI3Kα) inhibitor PIK-75[23], the PLK1 inhibitor 
BI-2536[24], the PI3K/mTOR inhibitor BEZ-235[25], 
and the Chk1/2 inhibitor AZD-7762 [26]. Further study 
of a panel of reported PI3K/mTOR inhibitors in HL60 
cells confirmed the results from the preliminary screen, 
with all compounds, including the clinical agent PKI-587, 
PF-04691502 and GDC-0941 possessing significant anti-
proliferative activity (Figure 1B). Notably, compounds 
with selectivity for members of the PI3K family were 
significantly weaker in this assay (Figure 1B). Compounds 
possessing MEK inhibitory activity (PD-0325901, CI-
1040) possessed potent activity selectively against the 
HL-60 cell line, further confirmed on repeat dose-response 
studies with the inclusion of the highly potent MEK 
inhibitors GSK-1120212 and PD-0325901 (Figure 1C).
Effect of compounds on neutrophil survival
Using a high-throughput live cell imaging 
approach reported previously [15], we examined the 
effect of the kinase inhibitors on the viability of bone 
marrow neutrophils to determine their potential to cause 
neutropenia (Figure 2). Because G-CSF and GM-CSF 
are dominant regulators of granulopoiesis and neutrophil 
survival, and are commonly used in a clinical setting to 
mobilize hematopoietic stem cells into the blood and 
increase neutrophil production [27-31], we treated cells 
with these cytokines immediately prior to drug exposure. 
The addition of either cytokine prevents constitutive 
neutrophil apoptosis thereby increasing the window 
for detection of changes in viability induced by drug 
Oncotarget57950www.impactjournals.com/oncotarget
Figure 1: Effects of kinase inhibition on the proliferation of leukemia cells. A. Human leukemia cell lines were treated with 
duplicate serial dilutions of kinase inhibitors and the effect on cell viability was determined by Cell Titer Glo assay after 48 hours. Data 
shown represents the mean IC50 of each condition from 2 independent experiments. HL-60 cells were treated with serial dilutions of 
mTor/PI3K B. and MEK C. inhibitors and the effect on cell viability was determined after 48 hours. Data shown is the mean ± SEM of 3 
independent experiments. Note, in some instances error bars are smaller than symbols displayed. 
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treatments. 
In G-CSF-primed neutrophils, nine kinase inhibitors 
reduced the viability of neutrophils (Figure 2A) whereas 
in GM-CSF-primed neutrophils, 25 kinase inhibitors 
significantly reduced neutrophil viability (Figure 2B). Of 
the kinase inhibitors active in G-CSF-primed neutrophils, 
all but one was also active in the GM-CSF treated group 
(Figure 2C). Given that both G-CSF and GM-CSF signal 
through the Janus kinases (JAKs), it is intriguing that only 
some JAK inhibitors included in the library significantly 
affected neutrophil viability (AZ960, AZD1480 and 
AT9283), whereas others did not (CP690550, CYT387 and 
Merck 5). The most active compounds in this screen are 
the cyclin-dependent kinase (CDK) inhibitors (SNS-032 
and Flavopiridol) and the PI3K p110α inhibitor PIK-75, 
which all induced rapid cell death in our assay system. 
Moreover, PIK-75 and SNS-032 induced cell death with 
similar potencies (Figure 2E) and kinetic profiles (Figure 
2F). In contrast to other PI3 kinase inhibitors examined in 
this study (including PI-93, PI-103, PIK-90 and PIK-294), 
PIK-75 was unique in its ability to induce rapid neutrophil 
cell death, suggesting that off-target effects of PIK-75 are 
responsible for the observed toxicity (vide infra). 
Human peripheral blood neutrophils from healthy 
donors were also studied to determine if kinase inhibitors 
elicit similar changes in lifespan to those of mouse 
neutrophils. Purified human neutrophils were primed for 
1 h with G-CSF or GM-CSF, and then treated for 18 h 
with SNS-032, PIK-75, GDC-0941, BI2536, BEZ235, 
AZD7762, SB202 or SB203. In the absence of kinase 
inhibitors, neutrophils primed with G-CSF or GM-
CSF maintained a viability of approximately 80%. 
Consistent with the data obtained from mouse bone 
marrow neutrophils, human peripheral blood neutrophils 
were sensitive to PIK-75 and SNS-032 but not the p38 
inhibitors SB202190 and SB203580 (Figure 3). Human 
neutrophils were sensitive to BI2536, BEZ235 and 
AZD7762 however the IC50 for these inhibitors were at 
Table 1: Compound and reported target
Compound Reported Targets Compound Reported Targets Compound Reported Targets
ABT-737 Bcl-2 proteins CYC-116 Aurora PI103 PI3K p110α
ABT-869 RTK CYT387 JAK1, JAK2, TYK2 PIK-294 PI3K p110α
AC220 FLT3, FMS, cKIT, PDGFR Danusertib AUR, BCR-ABL, FGFR PIK-75 PI3K p110α, CDK7, CDK9
AG13958 VEGF Dasatinib AUR, BCR-ABL, FGFR PIK-90 PI3K p110α
Akt-I-1 Akt1 E7080 VEGFR, FGFR, SCFR PLX4720 B-RafV600E
Akt-I-1,2 Akt1/2 Erlotinib EGFR Purvalanol-B CDK
AMG-47a Lck Flavopiridol CDKs R1487 p38 MAPK
AMG-Tie2-1 TIE-2 GDC-0941 PI3K RHO-15 ROCK1
AS-252424 PI3K p110γ Gefitinib EGFR RWJ-67657 p38MAPK
AT-7519 CDKs GSK690693 Akt1, Akt2 and Akt3 SB202190 p38 MAPK
AT9283 Aurora GW441756 TrkA SB203580 p38 MAPK
AV-412 EGFR IC87114 PI3K p110δ SB216763 GSK3
AV951 VEGFR Imatinib BCR-ABL SB242235 p38 MAP
Axitinib VEGF, PDGF, c-Kit JNJ38877605 c-MET SB590885 B-Raf
AZ-960 JAK1, JAK2, JAK3 JNJ7706621 CDK SD-06 p38MAPK
AZD1480 JAK2 Ki20227 cFMS SD169 p38α MAP kinase
AZD6244 MEK KU0063794 mTOR SNS-032 CDK2, CDK7, CDK9
AZD7762 CHK KU55933 ATM SNS-314 Aurora
BEZ-235 PI3K, mTOR KU57788 DNA-PK Sorafenib Raf & VEGFR
(R)-BI-2536 Plk1 Lapatinib EGFR, ErbB-2 SR3677 ROCK-II
BI-D1870 RSK Masatinib c-Kit SU-5402 FGFR, c-Kit
Bisindoylmaleimide X PKC Merck 5 JAK1, JAK2, JAK3, TYK2 SU-6668 VEGF, PDGFR and FGFR
BMS-3 LIMK Motesanib c-Kit, PDGFR, VEGFR Sunitinib cFMS,Flt3,Kit,PDGFR, RET & VEGFR
BMS-5 LIMK MP-470 Flt3,Met,Kit,c-Ret,PDGFR TAK-715 p38 MAPK
Bosutinib Bcr-Abl, Src Nilotinib BCR-ABL, cKit, PDGFR Tandutinib FLT3, PDGF, c-Kit
BX795 PDK1, TBK1 Pazopanib VEGF TGX221 PI3-K p110β
BX912 PDK1 PD0325901 MEK TOVOK EGFR, HER2
CC-401 JNK PF-562271 FAK Vandetanib VEGFR, EGFR
CI-1033 EGFR PF04217903 c-Met Vargatef VEGF, PDGFR, FGFR
CI-1040 MEK1, MKK5 PF431396 PYK2 VX-680 Aurora
CP-724714 ErbB2 PHA690509 CDK-A VX702 p38 MAPK
CP690550 JAK1, JAK2, JAK3 PI-93 PI3K p110α YM201636 PIK5
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Table 2: IC50 of inhibitors on cell lines.
Drug Name m SD m SD m SD m SD m SD m SD m SD m SD m SD m SD m SD m SD
ABT-737 0.05 0.03 3.52 0.04 0.53 0.23 2.91 0.2 10 0 1.88 0.03 6.12 5.08 0.71 0.32 0.14 0.03 6.2 1.31 10 0 4.41 1.45
ABT-869 0.01 0 10 0 10 0 5.22 6.76 9.49 0.45 10 0 10 0 10 0 0.01 0 10 0 10 0 10 0
AC220 0 0 9.13 1.23 10 0 6.12 5.49 10 0 9.86 0.2 6.33 5.19 9.88 0.18 0.01 0.01 10 0 10 0 3.36 2.6
AG13958 0 0 6.26 0.22 6.2 1.48 4.55 0.29 1.37 0.09 0.43 0.11 0.66 0.14 6.75 0.71 3.13 0.68 4.98 0.63 9.71 0.41 5.55 0.15
Akt-I-1 1.82 1.09 10 0 10 0 10 0 10 0 10 0 10 0 10 0 8.48 2.5 10 0 10 0 10 0
Akt-I-1,2 0.3 0.11 10 0 9.88 0.17 8.45 0.46 9.62 0.66 3.81 0.3 6.33 0.22 8.38 2.3 6.8 3.69 9.59 0.58 10 0 9.64 0.51
AMG-47a 0 0 2.7 0.32 0.34 0.08 2.93 1.26 0.02 0.01 0.01 0.01 0.01 0 2.5 1.41 0.36 0.07 0.17 0.07 1.3 0.04 4.03 0.3
AMG-Tie2-1 0 0.01 4.18 1.3 2.41 0.42 9.65 0.5 0.02 0.01 0.01 0 0.01 0 9.49 0.72 0.6 0.18 0.41 0.13 3.56 0.56 5.12 0.35
AP24534 0 0 1.18 0.03 0.65 0.11 0.82 0.15 0 0 0 0 0.01 0.01 1.38 1.12 0.01 0.01 0.3 0.02 1.21 0.62 0.58 0.11
AS-252424 1.53 0.49 10 0 10 0 10 0 9.58 0.72 6.02 0.4 10 0 10 0 3.26 1.74 3.18 0.56 10 0 8.01 0.08
AT-7519 0.1 0.01 1.79 0 0.14 0.02 0.27 0.01 1.18 0.23 1.56 0.36 1.41 0.44 0.49 0.1 0.1 0.02 0.32 0.05 0.24 0.07 0.15 0.03
AT9283 0.02 0.02 0.98 0.23 1.03 0.06 1.81 0.44 0.87 0.16 0.95 0.13 1.72 0.3 1.83 0.38 0.03 0.01 3.95 0.16 2.56 0.59 1.98 0.02
AV-412 0.14 0.1 1.69 0.1 0.95 0.37 1 0.35 1.48 0.4 0.87 0.01 1.88 1.39 0.93 0.16 0.15 0 1.21 0.17 0.91 0.03 0.66 0.07
AV951 0 0 10 0 7.66 0.72 10 0 0.41 0.13 0.17 0.02 0.15 0.07 9.1 1.28 0.52 0.07 10 0 10 0 9.02 1.39
Axitinib 0 0 7.87 3.02 6.09 5.54 2.62 1.56 0.64 0.16 0.19 0.01 0.21 0.02 7.43 3.63 2.5 0.98 8.89 1.57 10 0 3.97 3.56
AZ-960 0.29 0.23 0.29 0.01 0.48 0.1 0.43 0.05 1.92 0.67 0.62 0.05 1.86 1.49 1.51 0.31 0.43 0 0.69 0.04 2.03 1.97 0.17 0.03
AZD6244 0.6 0.53 10 0 0.12 0.02 10 0 7.91 2.85 0.5 0.03 1.96 0.82 10 0 5.24 1.62 0.07 0.02 7.01 0.46 9.18 1.16
AZD7762 0 0 0.2 0.05 0.45 0.05 0.44 0.08 0.18 0.09 0.23 0 0.18 0.1 0.15 0.12 0.01 0.01 0.17 0.02 0.17 0.02 0.12 0.01
BEZ-235 0.06 0.05 0.14 0.08 0.27 0.13 0.07 0.03 0.54 0.28 0.65 0.07 0.89 0.57 0.09 0.03 0.14 0.06 0.26 0.04 0.35 0.34 0.13 0.04
(R)-BI-2536 0.01 0 0.02 0.01 0.01 0 0.01 0 0.1 0.13 0.01 0 0.04 0.05 0.01 0 0.01 0 0.01 0 0.01 0 0.01 0.01
BI-D1870 0.99 0.71 4.7 1.74 3.36 1.36 4.07 1.72 8.13 1.73 3.37 0.17 2.03 1.28 4.61 0.37 1.25 0.2 1.02 0.26 2.4 0.17 3.29 0.45
Bisindoylmaleimide 
X 0.65 0.36 3.83 0.56 2.91 1.17 2.64 0.28 6.04 0.83 4.34 0.14 5.63 4.25 3.82 1.42 1.45 0.72 3.44 0.02 4.67 1.26 3.53 0.11
BMS-2 0.29 0.07 10 0 9.43 0.81 10 0 7.93 2 7.63 2.7 5.87 4.57 10 0 0.82 0.25 8.88 1.58 9.74 0.37 10 0
BMS-3 0.28 0.22 0.46 0.12 0.42 0.07 0.23 0.05 0.78 0.28 0.45 0.03 0.9 0.91 0.55 0.02 0.4 0.02 0.52 0.12 0.56 0.12 0.22 0.02
BMS-5 1.07 1.15 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
Bosutinib 0.56 0.05 1.01 0.26 3.73 3.69 0.91 0.14 0.88 0.17 0.23 0.02 0.21 0.07 1.7 1.79 0.66 0.07 1.48 0.08 1.89 0.1 0.91 0.52
BX795 0.12 0.08 5.43 1.66 10 0 9.08 1.3 9.27 0.64 2.38 0.1 4.41 1.83 10 0 0.1 0.05 10 0 10 0 2.07 0.43
BX912 0.12 0.1 10 0 8.47 2.16 7.57 0.15 7.13 3.5 9.63 0.53 7.25 3.89 3.37 2.25 0.05 0.01 10 0 10 0 2.57 0.14
CC-401 0.55 0.34 10 0 9.24 1.08 10 0 10 0 8.34 0.61 10 0 10 0 0.35 0.06 4.93 1.47 10 0 4.93 2.58
CI-1033 0.09 0.01 1.97 0.14 1.69 0.9 1.73 0.41 3.22 0.8 0.86 0.12 1.43 0.1 1.87 0.41 0.37 0.03 1.51 0.13 1.93 0.19 0.67 0.04
CI-1040 2.52 1.99 10 0 0.3 0.08 10 0 9.13 0.76 0.64 0.5 0.49 0.41 9.86 0.19 6.33 4.25 0.13 0.06 10 0 7.3 3.23
CP-724714 0.78 0.63 10 0 10 0 10 0 10 0 6.94 4.32 10 0 10 0 2.14 0.32 10 0 10 0 10 0
CP690550 2.81 2.52 7.83 3.06 10 0 10 0 10 0 10 0 5 7.07 10 0 9.34 1.32 10 0 10 0 0.94 0.4
CYC-116 0.26 0.22 2.18 0.67 6.25 4.37 1.97 1.97 8.46 0.7 4.91 0.99 3.61 2.09 1.44 0.04 0.09 0.04 7.67 2.53 8.96 1.47 0.48 0.04
Danusertib 0.05 0.01 5.75 0.97 0.56 0.06 4.32 0.25 0.14 0.06 0.24 0.04 0.43 0.16 0.66 0.38 0.04 0.01 0.87 0.38 10 0 0.13 0.17
Dasatinib 0.01 0 9.86 0.2 10 0 7.55 2.54 0 0 0 0 0.01 0.01 6.75 4.59 1.08 0.92 8.26 0.21 10 0 9.33 0.95
E7080 0 0.01 7.44 3.62 7.5 3.54 10 0 5.79 1.38 2.66 0.89 4.82 1.63 10 0 0.5 0.18 10 0 10 0 10 0
Erlotinib 1.68 1.45 8.52 0.26 9.26 1.04 6.73 0.12 10 0 5.48 0.02 5.68 0.11 10 0 1.9 0.21 10 0 10 0 10 0
Flavopiridol 0.11 0.03 0.22 0.01 0.12 0 0.18 0.01 0.55 0.13 0.25 0.01 0.42 0.16 0.23 0.03 0.15 0.03 0.14 0.02 0.13 0.02 0.1 0.01
GDC-0941 0.62 0.42 10 0 0.68 0.64 3.46 0.22 8.39 2.8 10 0 9.1 1.28 0.52 0.33 0.39 0.11 0.34 0.02 4.64 4.6 0.67 0.26
Gefitinib 0.9 0.61 9.42 0.82 10 0 5.59 2.16 10 0 4.96 0.72 9.1 1.27 8.34 2.34 2.22 0.71 7.32 1.61 10 0 5.53 2
GSK690693 1.75 1.18 10 0 6.3 0.21 0.41 0.16 10 0 10 0 10 0 0.26 0.17 2.35 0.68 10 0 10 0 0.25 0.01
GW441756 0.62 0.7 10 0 10 0 10 0 7.41 4.49 10 0 10 0 10 0 0.38 0.16 10 0 10 0 10 0
IC87114 4.43 3.95 10 0 10 0 10 0 10 0 10 0 10 0 10 0 5.77 1.75 10 0 10 0 5.09 6.94
Imatinib 0 0 10 0 10 0 9.55 0.64 0.25 0.12 0.12 0 0.16 0.08 10 0 8.82 1.71 10 0 10 0 10 0
JNJ38877605 7.43 4.8 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
JNJ7706621 1.32 0.23 4.8 0.34 1.76 0.58 3.39 0.17 5.23 1.01 3.48 0.27 5.91 0.92 7.81 1.79 1.28 0.22 2.86 0.44 2.05 0 1.09 0.4
Ki20227 0 0 10 0 10 0 10 0 10 0 9.44 0.79 10 0 10 0 6.62 1.51 10 0 10 0 5.25 0.76
KU0063794 0.06 0.04 5 2.08 4.97 0.12 4.12 2.01 4.94 1.73 4.39 0.55 5.12 3.07 3.32 0.01 0.61 0.1 2.04 0.62 3.54 2.97 0.63 0.18
KU55933 6.97 3.84 10 0 8.13 2.64 10 0 10 0 10 0 10 0 10 0 7.31 3.11 10 0 10 0 7.79 2.49
KU57788 3.6 1.94 8.94 0.38 6.2 4.55 9.14 1.21 10 0 10 0 7.44 1.58 9.93 0.1 2.52 2 1.51 0.35 6.59 4.83 3.87 1.84
Lapatinib 4.25 4.23 9.37 0.89 6.91 1.03 6.86 0.35 9.54 0.5 5.01 2.74 10 0 9.08 1.29 9.92 0.16 6.41 2.57 9.53 0.4 6.13 2.17
Masatinib 0 0 10 0 7.64 3.34 4.11 1.23 1.95 0.46 0.74 0.08 1.38 0.28 8.41 2.24 4.43 0.74 5.7 0.28 9.64 0.43 7.99 1.98
Merck -5 0.64 0.24 0.98 0.23 2.3 1.04 3.17 1.17 9.61 0.67 10 0 4.61 0.59 3 1.06 0.85 0.22 9.49 0.73 7.26 3.87 0.5 0.12
Motesanib 0.01 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1.89 0.54 10 0 10 0 10 0
MP-470 1.11 0.61 5.12 6.91 10 0 10 0 9.09 1.58 1.2 0.92 5.29 1.27 10 0 2.6 1.29 6.2 4.43 10 0 6.75 4.6
Nilotinib 0 0 7.71 0.72 5.39 3.78 5.76 0.21 0.01 0 0.01 0 0.01 0 10 0 6.83 3.75 2.13 0.14 7.55 3.47 4.25 0.16
Pazopanib 0.02 0 10 0 9.48 0.74 10 0 9.11 1.54 1.68 0.09 5.55 1.85 10 0 4.73 3.62 4.24 0.43 10 0 2.11 0.04
PD0325901 0.17 0.05 10 0 0 0 10 0 10 0 0.02 0 0.06 0.03 10 0 3.34 4.63 0.01 0 5.82 5.92 2 1.4
PF-562271 1.79 0.41 2.88 0.87 2.19 0.11 3.1 0.21 7.64 0.45 4.12 0.68 6.62 0.71 6 0.59 0.22 0.03 2.72 0.36 2.47 0.55 1.57 0.35
PF04217903 8.02 2.31 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
PF431396 1.52 0.36 4.07 0.74 1.64 0.05 3.61 0.18 7.1 2.25 5.24 0.28 6.32 0.36 6.42 1.28 0.16 0.03 2.96 0.08 3.66 1.69 1.23 0.14
PHA690509 5.31 5.04 2.88 0.75 2.35 0.05 3.21 0.73 5.98 0.8 3.93 0.3 5.39 1.07 4.68 1.69 5.89 4.75 6.23 0.42 5.98 0.88 1.05 0.13
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least 10-fold higher than for the cancer cell lines tested. 
Notably, human neutrophils were not sensitive to BI2536, 
BEZ235 and AZD7762 at the 1μM concentration used 
to screen mouse bone marrow neutrophils. These data 
suggest that similar regulatory pathways control human 
neutrophil lifespan and point to kinase inhibitors that offer 
a therapeutic window to target cancer cells while sparing 
bone marrow and peripheral blood neutrophils. 
To further explore the mechanisms underpinning 
the rapid neutrophil cell death induced by PIK-75 and 
SNS-032, we exposed neutrophils isolated from mice 
heterozygous for the Mcl-1 allele or deficient in the dual 
apoptosis regulators Bax and Bak. The cytotoxicity was 
accelerated by the loss of a single allele of Mcl-1 and 
completely abrogated by the loss of Bak and Bax (Figure 
4). The loss of a single allele of Mcl-1 reduced the EC50 
for both SNS-032 and PIK-75 from 182 nM and 228 nM 
in wild-type cells to 80 nM and 57 nM in Mcl-1+/- cells, 
respectively. These data clearly indicate that neutrophil 
cell death induced by these compounds is mediated 
through the apoptotic pathway.
Effect of compounds on hematopoietic myeloid 
progenitors
The kinase inhibitor library was also profiled 
against hematopoietic myeloid cells (defined as lin-c-
Kit+Sca-1- cells) to determine the effects of these agents 
on cells capable of generating neutrophils. In contrast to 
the sensitivity of neutrophils to a broad range of kinase 
inhibitors, hematopoietic myeloid progenitor cells (HPC) 
were largely insensitive to the kinase inhibitor panel, 
with the exception of PIK-75, which was active against 
both G-CSF- and GM-CSF-treated HPC (Figure 5A and 
5B). ABT-737, the small molecule antagonist of Bcl-2, 
Bcl-xL and Bcl-w, increased the death of hematopoietic 
progenitor cells (Figure 5C). In contrast, ABT-737 had 
no impact on mouse neutrophil viability (Figure 2). 
Similar results were obtained for a small panel of classical 
chemotherapeutics. Thus, a panel of eight commonly 
employed cytotoxic agents in leukemia showed profound 
activity against hematopoietic progenitor cells (Figure 5C) 
whereas only SN-38, the active metabolite of irinotecan, 
potently decreased neutrophil viability (Figure 5D). 
Priming hematopoietic progenitor cells with GM-CSF, 
but not G-CSF, partially protected cells from the effects of 
vincristine and etoposide (Figure 5E).
PI103 0.22 0.05 1.89 1.2 0.29 0.07 0.96 0.12 2.29 0.08 3.35 3.04 1.52 0.24 0.21 0.01 0.2 0.09 0.16 0 0.88 0.53 0.26 0.04
PIK-294 0.36 0.15 10 0 10 0 10 0 10 0 10 0 10 0 10 0 1.3 0.72 9.4 0.86 10 0 10 0
PIK-75 0.04 0.02 0.08 0 0.06 0.01 0.09 0 0.33 0.11 0.14 0.02 0.29 0.07 0.13 0.01 0.01 0 0.1 0.01 0.1 0.04 0.06 0.01
PIK-90 5.09 3.94 10 0 2.24 1.3 9.47 0.75 10 0 10 0 10 0 3.92 0.95 6.41 3.61 0.82 0.47 5.41 4.63 2.32 1.95
PIK-93 0.39 0.39 8.14 0.67 2.07 1.32 3.4 0.54 9.98 0.03 10 0 10 0 2.95 1.27 1.23 0.32 1.8 0.14 7.05 4.06 1.29 0.69
PLX4720 4.2 0.49 10 0 10 0 9.68 0.46 10 0 0.45 0.06 0.84 0.48 10 0 5.6 5.09 10 0 10 0 8.5 0.77
Purvalanol B    10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 9.13 1.74 10 0 10 0 10 0
R1487              1.41 1.13 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
RHO-15 0.19 0.13 10 0 10 0 10 0 7.75 3.9 2.11 0.47 5.14 3.3 10 0 7.22 3.23 10 0 10 0 9.64 0.51
RWJ-67657 3.59 4.34 10 0 10 0 10 0 10 0 5.77 0.54 10 0 10 0 8.28 2.02 10 0 10 0 8.05 2.76
SB202190 3.68 2.38 10 0 10 0 10 0 10 0 9.36 0.91 6.83 4.48 10 0 7 3.12 10 0 10 0 6.6 4.81
SB203580 1.45 1.92 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
SB242235 0.51 0.21 10 0 10 0 10 0 10 0 10 0 2.18 0.64 10 0 6.16 2.66 10 0 10 0 10 0
SB590885 1.3 0.2 5.26 0.61 1.41 0.01 3.76 1.06 4.06 0.9 5.01 0.16 5.04 0.39 5.93 0.52 2.59 0.06 2.71 0.07 3.31 0.12 3.42 0.03
SD-06 1.87 2.26 10 0 10 0 10 0 10 0 10 0 10 0 5.03 7.03 5.67 5 10 0 10 0 10 0
SD169 5.12 5.64 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
SMI-4a 0.13 0.07 10 0 10 0 10 0 2.74 1.72 4.54 0.53 5.78 0.69 10 0 9.71 0.58 10 0 10 0 10 0
SNS-032 0.09 0.03 1.33 0.48 0.1 0.04 0.16 0.05 0.72 0.24 0.61 0.3 0.58 0.28 0.29 0.09 0.15 0.04 0.19 0.01 0.14 0.03 0.07 0.01
SNS-314 0.02 0 10 0 6.62 4.39 9.01 1.4 9.11 1.54 0.83 0.25 8.15 2.62 3.58 5.06 0.01 0 10 0 7.37 3.73 5.04 1.83
Sorafenib 0 0 10 0 5.73 0.91 10 0 9.94 0.1 3.79 2.84 6.28 5.26 10 0 0.01 0 5.46 1.56 10 0 5.33 2.86
SR3677 0.75 0.1 10 0 9.1 1.27 10 0 10 0 1.53 0.56 8.05 2.76 10 0 2.64 1.76 10 0 10 0 5.96 0.21
SU-5402 1.43 0.45 10 0 10 0 10 0 10 0 9.28 1.02 10 0 10 0 0.73 0.26 10 0 10 0 10 0
SU-6668 0.84 0.43 10 0 10 0 10 0 8.11 3.28 10 0 10 0 10 0 5.11 2.22 10 0 10 0 10 0
Sunitinib 0.01 0 2.61 0.01 1.46 0.14 1.62 0.33 4.75 0.62 1.56 0.68 2.39 0.43 2.54 0.33 0.01 0 1.02 0.24 1.8 0.93 1.16 0.81
TAK-715 2.33 0.65 10 0 10 0 9.58 0.54 7.41 2.38 6.14 1.4 7.37 3.38 10 0 7.8 2.57 10 0 10 0 4.11 1.34
Tandutinib 0.02 0 10 0 7.58 2.75 4.38 0.24 8.85 1.13 6.6 0.46 7.91 2.95 9.77 0.33 0.08 0.02 4.87 0.73 7.42 0.15 7.44 0.12
TGX221 0.43 0.31 10 0 10 0 9.84 0.22 9.16 0.82 10 0 10 0 10 0 0.65 0.37 9.72 0.39 10 0 9.85 0.21
TOVOK 0.68 0.23 1.94 0.23 1.8 0.34 2.11 0.07 5.72 0.57 2.71 0.28 5.02 4.75 2.37 0.61 0.44 0.08 3.36 1.17 4.31 1.68 2.06 0.86
Vandetanib 0.19 0.07 10 0 7.28 1.77 6.28 0.44 2.73 0.73 0.82 0.05 1.51 0.25 6.79 1.8 0.86 0.16 10 0 10 0 9.46 0.76
Vargatef 0 0.01 2.97 0.05 3.55 1.13 2.7 0.11 0.59 0.36 0.24 0.02 0.46 0.03 3.69 1.49 0.04 0 3.44 1.29 5.85 0.32 6.31 1.13
VX-680 0.07 0.02 7.99 0.45 2.45 1.52 4.96 0.49 0.43 0.08 0.18 0.02 0.53 0.11 2.59 0.88 0.05 0 0.8 0.03 5.75 6.01 5.46 5.21
VX702 5.5 2.69 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0 10 0
YM201636 5.88 4.76 7.14 1.61 4.82 1.92 3.94 0.59 9.65 0.31 4.28 0.14 9.12 1.24 6.99 0.19 7.33 3.11 3.88 0.02 8.78 1.72 2.39 0.41
Values are shown in uM. For values less than 10 nM, they are represented as 0 uM. m:mean; SD:standard deviation.
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Figure 2: Viability of neutrophils in response to kinase inhibitors. A. & B. Viability analysis from live cell imaging of primary 
murine bone-marrow neutrophils primed with either G-CSF (A) or GM-CSF (B) in response to a panel of kinase inhibitors [1μM] over 
24 hours. Bar graphs display percentage viability relative to G-CSF- or GM-CSF-only primed controls at 12 hours. Red bars denote 
significance, p < 0.05 (corrected by Hommel’s modification of a Bonferroni t test). C. Summary of data in A) & B) highlighting the kinase 
inhibitors that significantly altered neutrophil viability. D. Viability of saline-treated primary murine bone-marrow neutrophils compared 
to neutrophils primed with GM-CSF or G-CSF for 21 hours. E. EC50 values for PIK-75 and SNS-032 as calculated from kinetic live cell 
imaging data of murine bone-marrow neutrophils shown in F., concentrations as marked. For all above, data represent mean ± SEM from 
three independent samples. 
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DISCUSSION
The discovery and development of kinase inhibitors 
targeted to specific kinases and kinase families has been a 
focus for therapeutic development for over 15 years [32, 
33]. Most kinase inhibitors bind to the highly conserved 
ATP binding site, and the vast majority possess a spectrum 
of activities across the kinome [18-20, 34, 35]. Cell-based 
profiling of libraries of kinase inhibitors therefore offers 
the possibility of studying inhibition of multiple signaling 
networks simultaneously in an unbiased manner. The 
kinase inhibitory profile of active compounds from these 
screens, when available, can then be analysed to determine 
the specific kinases, or kinase combinations, driving 
Figure 3: Assessment of human neutrophil viability in response to kinase inhibitor treatment. Human peripheral blood 
neutrophils from three healthy donors were primed with G-CSF or GM-CSF for 1 hour before addition of selected kinase inhibitors (as 
shown) or DMSO (control) at concentrations as indicated. Neutrophil viability was assessed after 18 hours of treatment, by propidium 
iodide exclusion measured by flow cytometry. Mean ± SEM shown. 
Figure 4: Neutrophils heterozygous for the Mcl-1 allele are more sensitive to CDK inhibition. A. SNS-032 and PIK75 
induce Bak/Bax-dependent apoptosis in primary murine bone marrow neutrophils that is sensitized by haplo-insufficiency of Mcl-1. Dose-
dependent changes to neutrophil viability induced by PIK-75 or SNS-032 were assessed by live cell imaging over 20 hours, with genotypes 
and concentrations as marked. EC50 values were calculated from the 12 hour time-point, data represent mean ± SEM with n = 3 per 
genotype. B. Immunoblot of Mcl-1 protein in bone marrow neutrophils from Mcl-1+/- mice, and from mouse embryonic fibroblasts as a 
control. 
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the phenotypic response. In addition, chemoproteomic 
methods can be employed to identify previously unknown 
biological targets of active compounds [36-38]. The 
deconvolution of active compounds from phenotypic 
screens using kinase-targeted compound libraries may 
therefore lead to the identification of new drug targets and 
target combinations for specific diseases, and a number of 
examples of this approach have been published recently, 
particularly from leukemia screens [39-41]. Furthermore, 
this approach may also be used to identify kinases whose 
inhibition may lead to potential toxicity [42, 43] . 
In this work we have screened a panel of kinase 
inhibitors against leukemia cell lines to identify 
compounds and kinase inhibitor classes that possess potent 
anti-leukemic activity. In parallel we have screened the 
same panel of compounds against primary mouse and 
human neutrophils to identify compounds and kinase 
inhibitory profiles that lead to neutrophil apoptosis, as a 
surrogate for predicting neutropenic potential. Screening 
the panel of kinase inhibitors against 12 leukemia cell 
lines identified four compounds (PIK-75, BI2536, 
BEZ235, AZD7762) that were potently cytotoxic to all 
lines examined. Thus, BI-2536, an inhibitor of polo-like 
kinases 1, 2 and 3 [24], and recently identified to potently 
inhibit the BET bromodomain BRD4[44, 45], possessed 
an IC50 <300 nM across all cell lines examined. Given 
the polo-like kinases are intimately involved in cell 
division through association with tubulin[46], and that 
BRD4 inhibition can affect both cell cycle progression 
[47], recruitment of oncogenic transcription factors and 
expression of key survival proteins [48], this potent 
activity is unsurprising. Indeed, PLK1 is overexpressed 
in AML, and PLK inhibitors have been shown to possess 
activity in AML [49-51] and CML [52]. 
The potent activity of the pan PI3K/mTOR inhibitor 
BEZ-235 across the panel is also consistent with published 
data, and further supported by the activity of the recently 
described PI3K/mTOR inhibitors, PF-04691502 [53] and 
PKI-587 [54] against HL-60 cells (Figure 1C). BEZ-235 
has shown activity in preclinical studies in AML [55] and 
has been shown to cause a decrease in Mcl-1 levels [56], 
a critical survival factor for AML and for neutrophils [57, 
58]. Similarly, the Chk1 inhibitor AZD-7762 displayed 
high potency in cell lines, and selective Chk1 inhibitors 
have been shown to be cytotoxic to leukemia cells alone 
[59], or in combination with other drugs [60, 61]. The 
significant number of active agents against the FLT3-
ITD positive AML line MV4;11, reflects the number of 
kinase inhibitors that possess FLT3 inhibitory activity 
either by design (e.g. AC220, tandutinib) or the known 
propensity of many kinase inhibitors to bind to FLT3 with 
high affinity [18]. The selective activity of MEK inhibitors 
GSK-1120212, PD-0325901 and CI-1040 against HL60 
cells is also consistent with reported activity of MEK 
inhibitors in preclinical AML studies [62, 63], and indeed 
MEK inhibitors have been studied clinically in AML [64]. 
Taken together, these data clearly indicate our parallel 
screening approach can identify molecular targets, and 
indeed specific kinase inhibitors, with relevance to dose-
limiting toxicities relevant to leukemia treatment.
Our parallel study exploring the effects of the 
kinase inhibitor library on neutrophil viability using real-
time image analysis identified some surprising results. 
Our data clearly show that the potent CDK inhibitors 
flavopiridol and SNS-032 have a significant impact on 
neutrophil viability. That PIK-75, a nominally selective 
inhibitor of PI3K p110α [23], induces neutrophil death 
with similar kinetics to SNS-032 is consistent with recent 
reports showing that this compound potently inhibits 
CDK7 and CDK9 [65, 66]. The cell death induced by 
SNS-032 and PIK-75 was accelerated by the loss of a 
single allele of Mcl-1 and completely abrogated by the 
loss of Bak and Bax indicating cell death proceeds via 
the intrinsic apoptotic pathway. Human neutrophils 
express CDK7 and CDK9, which influence transcription 
via the phosphorylation of RNA polymerase II [67]. 
The abrogation of protein synthesis by CDK9 inhibitors 
reduces intracellular levels of short-lived proteins such as 
Mcl-1, a critical pro-survival protein in neutrophils whose 
expression level is intimately linked with neutrophil 
survival [68-70]. Indeed, clinical experience with SNS-
032 in patients with chronic lymphocytic leukemia and 
multiple myeloma identified neutropenia as the dose-
limiting side-effect, thought to be a consequence of 
decreased expression of Mcl-1 and XIAP [71]. The effect 
of CDK9 inhibition on neutrophils has been reported 
previously [67], and CDK inhibitors have been proposed 
as potential anti-inflammatory agents via actions on 
Mcl-1 [72-74]. However, the mechanism of action of 
CDK inhibition has been only previously inferred from 
analysis of Mcl-1 protein levels [67, 70, 72, 75, 76]. Using 
a genetic approach, we now show that the loss of Mcl-1 
protein increases the sensitivity of primary bone marrow 
neutrophils to SNS-032 and the inhibitor PIK-75. We 
cannot, however, exclude a role for PI3 kinase signaling 
in the death-inducing effects of PIK-75 because Mcl-1 
expression is also regulated in part by PI3 kinase [77], 
though notably other PI3K inhibitors in the kinase panel 
did not induce neutrophil death with the same kinetics. 
The effect of inhibitors of the PI3K pathway on neutrophil 
viability was variable. Whilst the PI3K/mTOR inhibitor 
BEZ-235 had minimal impact, some neutrophil toxicity 
was observed for the inhibitors (PI-93, PI-103, PIK-294) 
over the timeframe of the experiment. Other investigators 
have noted important roles for PI3 kinase pathways in the 
viability of GM-CSF-stimulated neutrophils [78] which is 
consistent with our data (Figure 2B). The limited effect 
of Jak inhibitors on neutrophil viability is also consistent 
with previous studies using mice with a conditional 
deletion of STAT3 [79, 80]. However, the cytotoxicity 
of the JAK inhibitors TG-101348, AT-9283 and AZD-
1480 may reflect undesired off-target activity of these 
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Figure 5: Viability of hematopoietic myeloid progenitor cells in response to kinase inhibitors or chemotherapeutics. A. 
& B. Viability analysis from live cell imaging of primary murine myeloid HPCs primed with either GM-CSF (A) or G-CSF (B) in response 
to a panel of kinase inhibitors [1μM] over 24 hours. Significant results (p < 0.05) denoted in red (when adjusted for multiple comparison 
testing) or orange (not adjusted for multiple comparison testing). (C & D) Dose-dependent effects of common chemotherapeutics on GM-
CSF-primed primary murine myeloid HPCs C. or GM-CSF-primed primary murine bone-marrow neutrophils D. as assessed by live cell 
imaging analysis (concentrations as marked). E. Comparison of G-CSF (red/orange) or GM-CSF (blue) priming of myeloid HPCs before 
treatment with chemotherapeutics as assessed by live cell imaging (concentrations as marked). Bar graphs display percentage viability 
relative to G-CSF- or GM-CSF-only primed controls at 12 hours. Mean ± SEM with n = 3 independent samples. * p < 0.05. F. Venn diagram 
representing compounds that induce apoptosis of all leukemia cell lines tested (EC50 < 1 μM), and their apoptosis-inducing potential on 
hematopoietic progenitor cells and neutrophils.
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compounds (e.g. aurora kinase activity for TG-101348 and 
AT-9283; multiple targets for TG-101348 [44, 81]), and 
notably clinical trials of all three compounds have been 
discontinued. 
In contrast to neutrophils, hematopoietic myeloid 
progenitor cells were less sensitive to the kinase inhibitor 
library, with the exception of PIK-75 (Figure 5), though 
this likely reflects the multikinase activity of this 
compound [66]. The small molecule antagonist of Bcl-
2, Bcl-xL and Bcl-w, ABT-737, which showed minimal 
effects on neutrophils in our assay system, increased the 
death of hematopoietic myeloid progenitor cells. This is 
consistent with the reported role of Bcl-2 in the viability 
of hematopoietic progenitor cells [82]. By contrast, mature 
post-mitotic neutrophils were not sensitive to the panel of 
chemotherapeutics, with the exception of SN-38, whereas 
hematopoietic myeloid progenitor cells were exquisitely 
sensitive to these chemotherapeutics. Interestingly, 
although carboplatin and docetaxel induce neutropenia in 
the clinic [83, 84], no effects on hematopoietic myeloid 
progenitor cells or neutrophils were observed in these 
assays, suggesting that these cytotoxic drugs may induce 
the death of non-hematopoietic cells in the bone marrow 
niche or exert cytostatic effects on hematopoietic cells that 
impair neutrophil production. 
In summary, our combined screening approach 
allows for the identification of specific compounds 
and kinase target combinations with utility in treating 
leukemia and lymphomas, whilst at the same time 
identifying whether these compounds have the potential 
to cause neutropenia through toxicity to neutrophils and 
their progenitors. Further, the kinase inhibitory properties 
of the compounds employed provides an opportunity to 
identify the dominant pathways controlling neutrophil 
viability. Our data demonstrates that compounds with 
significant CDK9 (and CDK7) activity are likely to be 
toxic to neutrophils. Conversely, PLK inhibitors and those 
targeting PIK3/mTOR and separately MEK and Chk1, are 
likely to have minimal neutropenic potential whilst having 
considerable activity against leukemias. 
MATERIALS AND METHODS
Cell lines and culture
Leukemia and lymphoma cell lines were grown in 
RPMI containing 10% FCS. Cells were obtained from 
ATCC (HEL 92.1.7, Jurkat, MEG01, THP-1, MV4;11, 
KU-812, U937), the NCI (K562, HL-60, MOLT-4) or 
DSMZ (EOL-1, OCI-AML3) and used at low passage. 
Cell lines are routinely tested for mycoplasma and 
genotyped by short tandem repeating (STR) profiling to 
confirm identity.
Cell proliferation assay
Compounds were obtained from SynMedChem and 
dissolved at 10 μM in DMSO. Serial 2-fold dilutions of 
each compound were prepared in DMSO using a liquid 
handling robot (Janus, Perkin Elmer). Each dilution 
(100nL) was transferred to duplicate tissue culture plates 
containing 50 μL of media containing 5 × 103 cells using 
a 384 well pin tool. Cells were incubated for 48 h and cell 
viability was determined using Cell Titer Glow reagents 
as described by the manufacturer (Promega). Data was 
acquired using a luminescent plate reader (Envision, 
Perkin Elmer) and analysed using Activity Base (IDBS, 
Guilford, UK) and visualised using Spotfire (TIBCO, Palo 
Alto, CA) as described previously [14]. Each cell line 
was assayed in independent experiments on at least two 
occasions. The activity of PI3K/mTor and MEK inhibitors 
in HL-60 cells were validated using Cell Titer Glo assays 
in 96-well plates. Serial 2-fold dilutions of each compound 
were prepared in media containing 0.2% DMSO and 50 
μl of each dilution was added to 104 cells in 50 μl of 
media. Cells were incubated for 48 h and cell viability 
was determined using Cell Titer Glow assay as described 
above.
Mice
C57BL/6J, Mcl1+/-, Bak-/- Bax-/ΔvavCre and littermate 
controls on a C57BL/6J background were bred at the 
Walter and Eliza Hall Institute and analyzed at 6-10 weeks 
of age after CO2 asphyxiation. All experiments were 
carried out in accordance with institutional animal ethics 
guidelines and approval.
Neutrophil preparation
Mouse bone marrow neutrophils were prepared as 
described [15]. Neutrophils were resuspended in phenol 
red-free DMEM/10% FBS for imaging studies. The purity 
of neutrophil preparations was routinely 96% ± 4% (Mean 
± SD, n = 50) as assessed by cytology following May-
Grünwald/Giemsa staining. 
Myeloid progenitor cell preparation
For purification of myeloid progenitor cells, bone 
marrow cells were collected in DMEM/10% FCS. After 
red cell lysis, cells were stained with biotin-conjugated 
antibodies against Ter119, Gr-1, Mac-1, B220, CD4, 
CD8 and IL-7Rα and incubated with streptavidin-
microbeads (Miltenyi Biotech). Lineage positive cells 
were depleted by magnetic separation using MACS LS 
columns and QuadroMACSTM separator magnets (Miltenyi 
Biotech). Hematopoietic myeloid progenitor cells that 
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were propidium iodide (PI) negative, lineage-negative, 
Sca-1 negative and c-Kit positive, were sorted and 
collected by flow cytometry on a FACSAria or Diva (BD 
Biosciences). For imaging studies, cells were resuspended 
in StemPro-34 SFM (Invitrogen). Cells were cultured in 
10 ng/mL human G-CSF (Neupogen, Amgen), 10 ng/mL 
recombinant mouse GM-CSF or 10 ng/mL recombinant 
human GM-CSF.
Human peripheral blood neutrophils
Peripheral blood was obtained from normal healthy 
donors in 2015 after obtaining informed written consent 
under an approved institutional review board protocol at 
Boston Children’s Hospital. Donors were 18 years of age 
or older and had not taken anti-inflammatory medications 
during the 2 weeks before donating. Red blood cells were 
removed from 5 mL blood by hypotonic lysis in 45 mL 
0.168 M NH4Cl, 11.9 mM NaHCO3, 10 μM EDTA, pH7.3 
on ice before immediate centrifugation at 400 × g for 5 
min. Human neutrophils were then isolated on a three-
layer Percoll gradient as described for mouse bone marrow 
neutrophils as described[16]. The purity of neutrophil 
preparations was 93 ± 1% (mean ± SD, n = 3) as assessed 
by May-Grünwald Giemsa staining. Contaminating cells 
were comprised of eosinophils (7 ± 1%). Neutrophils were 
resuspended in DMEM/10%FBS, and primed with 10 ng/
mL recombinant human G-CSF (Amgen) or 10 ng/mL 
recombinant human GM-CSF (Leukine, Sargramostim) 
for 1 h. Compounds or DMSO carrier were added for 
16 h. Viability was assessed by staining neutrophils with 
propidium iodide and analyzing on a BD Fortessa.
Compounds
Kinase inhibitors were purchased from SYN kinase 
(Melbourne, Australia) and were used at 1 μM, unless 
otherwise specified, with dilutions performed in assay 
buffer containing 0.1% DMSO. Chemotherapeutics, 
diluted in PBS immediately prior to treatment, were 
obtained from the following suppliers: ABT-737 (AbbVie); 
Bortezomib (Janssen); Carboplatin, Doxorubicin, 
Etoposide, Vincristine (DBL); Docetaxel (Aventis); 
Gemcitabine (Ebewe, InterPharma); and, 7-ethyl-10-
hydroxycamptothecin (SN-38) (LKT Laboratories). 
Live cell imaging and quantitative analysis
Cells were labeled with 160 nM Cell Tracker Green 
(Invitrogen) and plated in 96- or 384-well optical bottom 
assay plates (Nunc, BD) at 105 or 1.5 × 103 cells per well, 
respectively. Viability was monitored using 2 μg/mL PI 
(Sigma). Images were captured every 30-60 min by the 
Zeiss Axiovert 200M Microscope at 37 ºC/10% CO2. 
Quantitative analysis was performed using a custom-
scripted MetaMorph (Molecular Devices) journal suite 
incorporating the count nuclei function, reconstruction 
& subtraction functions and Integrated Morphometry 
Analysis to select and analyze cells of interest. The 
MetaMorph script is available upon request. 
Statistical analysis
Unless otherwise specified, data are presented 
as mean ± SEM of n = 3. Where n = 6, comparisons 
were made using a statistical modeling package 
CompareGrowthCurves [17]. Comparisons were 
performed using a Student’s t-test and adjusted by 
Hommel’s Modification of the Bonferroni t test.
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